Muutke küpsiste eelistusi

E-raamat: Intelligent Drug Development: Trials and Errors in Clinical Research

(Chief Consultant, Competitive Drug Development LLC)
  • Formaat: 240 pages
  • Ilmumisaeg: 15-Apr-2014
  • Kirjastus: Oxford University Press Inc
  • Keel: eng
  • ISBN-13: 9780190200657
  • Formaat - PDF+DRM
  • Hind: 49,13 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: 240 pages
  • Ilmumisaeg: 15-Apr-2014
  • Kirjastus: Oxford University Press Inc
  • Keel: eng
  • ISBN-13: 9780190200657

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Clinical research is heavily regulated and involves coordination of numerous pharmaceutical-related disciplines. Each individual trial involves contractual, regulatory, and ethics approval at each site and in each country. Clinical trials have become so complex and government requirements so stringent that researchers often approach trials too cautiously, convinced that the process is bound to be insurmountably complicated and riddled with roadblocks. A step back is needed, an objective examination of the drug development process as a whole, and recommendations made for streamlining the process at all stages.
With Intelligent Drug Development, Michael Tansey systematically addresses the key elements that affect the quality, timeliness, and cost-effectiveness of the drug-development process, and identifies steps that can be adjusted and made more efficient. Tansey uses his own experiences conducting clinical trials to create a guide that provides flexible, adaptable ways of implementing the necessary processes of development. Moreover, the processes described in the book are not dependent either on a particular company structure or on any specific technology; thus, Tansey's approach can be implemented at any company, regardless of size. The book includes specific examples that illustrate some of the ways in which the principles can be applied, as well as suggestions for providing a better context in which the changes can be implemented. The protocols for drug development and clinical research have grown increasingly complex in recent years, making Intelligent Drug Development a needed examination of the pharmaceutical process.

Arvustused

Featured in the Journal of Clinical Research Best Practices, and selected for The First Clinical Research Bookshelf: Essential reading for clinical research professionals.

Acknowledgments vii
PART ONE Setting the Scene
Introduction: Cutting the Gordian Knot 3(6)
1 Aiming for Excellence
9(22)
PART TWO Planning: From Chaos to Cosmos
2 The Target Product Profile and Its Uses
31(16)
3 Planning the Individual Clinical Trial
47(10)
PART THREE The Practicable Protocol
4 Distilling the Essence of the Protocol: The Protocol Synopsis
57(11)
5 Redistillation: Eliminating Impurities by Carrying out Protocol Feasibility
68(22)
6 The Optimal Blend: The Approved Synopsis and the Final Protocol
90(13)
PART FOUR The Sponsor, The Physician, and The Patient: The Eternal Clinical Trial Triangle
7 Of Chickens and Eggs: The Sponsor's Dilemma
103(20)
8 Clinician or Clinical Trialist: The Physician's Dilemma
123(53)
9 What about the Customer? The Patient's Dilemma
176(11)
PART FIVE And Another Thing...
10 About Time: Making Meetings Matter
187(15)
11 The Brain-Scrambling, Fit-Inducing, Mind-Numbing Technicolor Laser Show
202(11)
References 213(4)
Index 217
Michael Tansey is former Vice President of La Jolla Pharmaceutical Company. He is currently an R&D consultant to pharmaceutical and biotechnology companies.